vimarsana.com
Home
Live Updates
Study: Fenofibrate not a useful strategy for decreasing COVI
Study: Fenofibrate not a useful strategy for decreasing COVI
Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity
After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists.
Related Keywords
United States ,
America ,
American ,
Julio Chirinos ,
Jordanab Cohen ,
Emily Henderson ,
Training Program In Cardiovascular Biology ,
Lab Diagnostics Automation ,
Drug Administration ,
University Of Pennsylvania ,
American Heart Association Scientific Sessions ,
Lab Diagnostics Automation Industry ,
Perelman School Of Medicine ,
Penn Medicine ,
American Heart Association ,
Scientific Sessions ,
Cardiovascular Medicine ,
Cardiovascular Biology ,
Perelman School ,
United States Food ,
Automation Industry Focus ,
North America ,
South America ,
Cholesterol ,
Covid 19 ,
Fenofibrate ,
Clinical Trial ,
Drugs ,
Efficacy ,
Heart ,
Hospital ,
N Vitro ,
Laboratory ,
Medicine ,
Metabolism ,
Placebo ,
Research ,
Cars ,
Virus ,